TICARCILLIN

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H16N2O6S2
Molecular Weight	384.427
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](C(O)=O)C3=CSC=C3)C(O)=O

InChI

InChIKey=OHKOGUYZJXTSFX-KZFFXBSXSA-N

InChI=1S/C15H16N2O6S2/c1-15(2)9(14(22)23)17-11(19)8(12(17)25-15)16-10(18)7(13(20)21)6-3-4-24-5-6/h3-5,7-9,12H,1-2H3,(H,16,18)(H,20,21)(H,22,23)/t7-,8-,9+,12-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2387996 | https://www.drugs.com/pro/ticar.html

Ticarcillin (also known as Ticar) is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative aerobic and anaerobic bacteria. Ticarcillin is not absorbed orally; therefore, it must be given intravenously or intramuscularly. Ticarcillin's antibiotic properties arise from its ability to prevent cross-linking of peptidoglycan during cell wall synthesis when the bacteria tries to divide, causing death. Usage of ticar was discontinued.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 233 Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2387996	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Sepsis 71 Sources: https://www.drugs.com/pro/ticar.html	Curative	Approved 8429	TICAR Approved Use Unknown Launch Date 1976
Skin and soft tissue infections 33 Sources: https://www.drugs.com/pro/ticar.html	Curative	Approved 8429	TICAR Approved Use Unknown Launch Date 1976
Acute and chronic respiratory tract infections 6 Sources: https://www.drugs.com/pro/ticar.html	Curative	Approved 8429	TICAR Approved Use Unknown Launch Date 1976
Intra-abdominal infections 49 Sources: https://www.drugs.com/pro/ticar.html	Curative	Approved 8429	TICAR Approved Use Unknown Launch Date 1976
Infections of the female pelvis and genital tract 6 Sources: https://www.drugs.com/pro/ticar.html	Curative	Approved 8429	TICAR Approved Use Unknown Launch Date 1976

C_max

Value	Dose	Co-administered	Analyte	Population
324 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM	CLAVULANATE POTASSIUM	TICARCILLIN serum	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
431.5 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID	CLAVULANIC ACID	TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
621.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID	CLAVULANIC ACID	TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
576.2 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered:		TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
485 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM	CLAVULANATE POTASSIUM	TICARCILLIN serum	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
538 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID	CLAVULANIC ACID	TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
890 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID	CLAVULANIC ACID	TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
747 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered:		TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
339 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	50 mg/kg bw single, intravenous dose: 50 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM	CLAVULANATE POTASSIUM	TICARCILLIN serum	Homo sapiens population: UNKNOWN age: CHILD sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
76 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7140806/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered:		TICARCILLIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM	CLAVULANATE POTASSIUM	TICARCILLIN serum	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
80.7 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID	CLAVULANIC ACID	TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
84.7 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANIC ACID	CLAVULANIC ACID	TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
74.8 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3722046/	5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered:		TICARCILLIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	50 mg/kg bw single, intravenous dose: 50 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM	CLAVULANATE POTASSIUM	TICARCILLIN serum	Homo sapiens population: UNKNOWN age: CHILD sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
55% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	3 g single, intravenous dose: 3 g route of administration: Intravenous experiment type: SINGLE co-administered: CLAVULANATE POTASSIUM	CLAVULANATE POTASSIUM	TICARCILLIN serum	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Co-administed with:: ciavuianate potassium iv(200 mg/kg/day) Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90	unhealthy, 19-91 n = 37 Health Status: unhealthy Condition: Urinary tract infections Age Group: 19-91 Sex: M+F Population Size: 37 Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90	Disc. AE: Rash, Nausea... Other AEs: Elevated liver enzymes, Eosinophilia... AEs leading to discontinuation/dose reduction: Rash (grade 1, 2.7%) Nausea (grade 2, 2.7%) Other AEs: Elevated liver enzymes Eosinophilia Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90
80 mg/kg single, intravenous Highest studied dose Dose: 80 mg/kg Route: intravenous Route: single Dose: 80 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/3777901 Page: p.360	healthy, 22-26 n = 8 Health Status: healthy Age Group: 22-26 Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/3777901 Page: p.360	Sources: https://pubmed.ncbi.nlm.nih.gov/3777901 Page: p.360
3 g 5 times / day multiple, intravenous Overdose Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Co-administed with:: ciavuianate potassium iv(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1	Other AEs: Convulsions... Other AEs: Convulsions Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1
3 g 5 times / day multiple, intravenous Recommended Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Co-administed with:: ciavuianate potassium iv(100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1	Other AEs: Hypersensitivity reaction, Diarrhea, Clostridium difficile... Other AEs: Hypersensitivity reaction (grade 3-5) Diarrhea, Clostridium difficile Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Elevated liver enzymes		3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Co-administed with:: ciavuianate potassium iv(200 mg/kg/day) Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90	unhealthy, 19-91 n = 37 Health Status: unhealthy Condition: Urinary tract infections Age Group: 19-91 Sex: M+F Population Size: 37 Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90
Eosinophilia		3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Co-administed with:: ciavuianate potassium iv(200 mg/kg/day) Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90	unhealthy, 19-91 n = 37 Health Status: unhealthy Condition: Urinary tract infections Age Group: 19-91 Sex: M+F Population Size: 37 Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90
Rash	grade 1, 2.7% Disc. AE	3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Co-administed with:: ciavuianate potassium iv(200 mg/kg/day) Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90	unhealthy, 19-91 n = 37 Health Status: unhealthy Condition: Urinary tract infections Age Group: 19-91 Sex: M+F Population Size: 37 Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90
Nausea	grade 2, 2.7% Disc. AE	3 g 4 times / day multiple, intravenous Recommended Dose: 3 g, 4 times / day Route: intravenous Route: multiple Dose: 3 g, 4 times / day Co-administed with:: ciavuianate potassium iv(200 mg/kg/day) Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90	unhealthy, 19-91 n = 37 Health Status: unhealthy Condition: Urinary tract infections Age Group: 19-91 Sex: M+F Population Size: 37 Sources: https://pubmed.ncbi.nlm.nih.gov/4073101 Page: p.90
Convulsions		3 g 5 times / day multiple, intravenous Overdose Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Co-administed with:: ciavuianate potassium iv(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1
Diarrhea, Clostridium difficile		3 g 5 times / day multiple, intravenous Recommended Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Co-administed with:: ciavuianate potassium iv(100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1
Hypersensitivity reaction	grade 3-5	3 g 5 times / day multiple, intravenous Recommended Dose: 3 g, 5 times / day Route: intravenous Route: multiple Dose: 3 g, 5 times / day Co-administed with:: ciavuianate potassium iv(100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Bacterial infections Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf Page: p.1

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
UGT2B15 64 ALDH 8 OAT1 599 OAT2 145 OATP1B3 706

Drug as perpetrator

Target	Modality	Activity
ALDH 8	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804443/	no
OAT2 147	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804443/	no
OATP1B3 715	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804443/	no
UGT2B15 64	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804443/	no
OAT1 603	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804443/	yes [IC50 1833 uM]

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:9587	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9587
ChemicalBook	CB7224768	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7224768
ZINC	ZINC000003831540	http://zinc15.docking.org/substances/ZINC000003831540
eMolecules	29537804	https://www.emolecules.com/cgi-bin/more?vid=29537804

PubMed

Title	Date	PubMed
Epitope analysis of aztreonam by antiaztreonam monoclonal antibodies and possible consequences in beta-lactams hypersensitivity.	1992	1384868
Antimicrobial susceptibility of respiratory isolates of Enterobacteriaceae and Staphylococcus aureus in Italy: incidence and trends over the period 1997-1999.	2001 Dec	11837636
[Correlation between sensitivity to fosfomycin and the presence of penicillinase PSE-1 in Pseudomonas aeruginosa].	2001 Feb	11265218
Stability of piperacillin and ticarcillin in AutoDose infusion system bags.	2001 Nov	11724082
Comparative in vitro activity of temocillin and other antimicrobial agents against Enterobacteriaceae isolated from patients admitted to five Belgian hospitals.	2001 Nov-Dec	11881320
Systematic review and meta-analysis of antibiotic therapy for bone and joint infections.	2001 Oct	11871494
In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations.	2001 Sep-Oct	11687317
[Identification and susceptibility to antimicrobial agents of strictly anaerobic bacteria isolated from hospitalized patients].	2002	12632658
Patterns and mechanisms of resistance to beta-lactams and beta-lactamase inhibitors in uropathogenic Escherichia coli isolated from dogs in Portugal.	2002 Jan	11751770
Growth of cell-wall-deficient variants of Enterobacter cloacae facilitates beta-lactamase derepressed mutants.	2002 May	12007848
Natural antibiotic susceptibility of Enterobacter amnigenus, Enterobacter cancerogenus, Enterobacter gergoviae and Enterobacter sakazakii strains.	2002 Sep	12427217
Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma.	2003 Apr	12959681
Natural antimicrobial susceptibilities of strains of 'unusual' Serratia species: S. ficaria, S. fonticola, S. odorifera, S. plymuthica and S. rubidaea.	2003 Apr	12654765
Application of MEKC for determination of ticarcillin and clavulanic acid in Timentin intravenous preparation.	2003 Apr 24	12852449
[Enterobacterial susceptibility to antibiotics in northern Lebanon (1998-2001)].	2003 Apr-Jun	14530123
Early antibiotic selection and efficient rooting and acclimatization improve the production of transgenic plum plants (Prunus domestica L.).	2003 Aug	12827433
Late bacterial keratitis after implantation of intrastromal corneal ring segments.	2003 Feb	12648660
[Phenotypes of beta-lactam resistance in the genus Aeromonas].	2003 Jul	14567197
Natural antibiotic susceptibility of strains of Serratia marcescens and the S. liquefaciens complex: S. liquefaciens sensu stricto, S. proteamaculans and S. grimesii.	2003 Jul	12842326
[Community-acquired Pseudomonas aeruginosa bacteremic pneumonia in a "healthy" subject].	2003 Jul 12	12947742
Ticarcillin-clavulanic acid plus amikacin versus ceftazidime plus amikacin in the empirical treatment of fever in acute leukemia: a prospective randomized trial.	2003 Jun	12868552
Cefepime versus ticarcillin and clavulanate potassium and aztreonam for febrile neutropenia therapy in high-dose chemotherapy patients.	2003 Jun	12796602
Beta-lactamase production in Prevotella and in vitro susceptibilities to selected beta-lactam antibiotics [corrected].	2003 Mar	12636990
Retrospective analysis of antibiotic susceptibility patterns of respiratory isolates of Pseudomonas aeruginosa in a Turkish University Hospital.	2003 Mar 7	12665428
[Assay of Acinetobacter SPP drug-resistance by Kirby-Bauer and Etest method].	2003 May	12754133
Sequence analysis and biochemical characterisation of chromosomal CAV-1 (Aeromonas caviae), the parental cephalosporinase of plasmid-mediated AmpC 'FOX' cluster.	2003 May 16	12757951
Natural antimicrobial susceptibilities and biochemical profiles of Yersinia enterocolitica-like strains: Y. frederiksenii, Y. intermedia, Y. kristensenii and Y. rohdei.	2003 Sep 22	13129648
Simultaneous determination of ticarcillin and clavulanate in rabbit serum and tissue cage fluid by liquid chromatography.	2003 Sep 5	12954375
Beta-lactamase characterization in Escherichia coli isolates with diminished susceptibility or resistance to extended-spectrum cephalosporins recovered from sick animals in Spain.	2003 Summer	12820806
[Antibiotic susceptibility and occurrence of ESBL in Pseudomonas aeruginosa strains isolated from different clinical specimens].	2004	15773503
An epidemiological analysis of Stenotrophomonas maltophilia strains in a university hospital.	2004 Apr	15118205
Comparative activity of beta-lactam agents (carbapenem excepted) against Pseudomonas aeruginosa strains with CARB or OXA beta-lactamases.	2004 Apr	15084803
A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.	2004 Aug	15289131
Detection and assay of beta-lactamases in clinical and non-clinical strains of Yersinia enterocolitica biovar 1A.	2004 Aug	15269194
[Pseudomonas aeruginosa: a multicentric study of antibiotic resistance (1999-2000)].	2004 Dec	15822507
[Infectious cellulitis and Shewanella alga septicemia in an immunocompetent patient].	2004 Dec	15692446
Resistance to beta-lactam antibiotics in Aeromonas hydrophila isolated from rainbow trout (Oncorhynchus mykiss).	2004 Sep	15492935
Antimicrobial resistance of selected Salmonella isolates from food animals and food in Alberta.	2005 Feb	15825516
Acinetobacter baumanii folliculitis in a patient with AIDS.	2005 May	15807684

Patents

Sample Use Guides

In Vivo Use Guide

Bacterial septicemia: 200 to 300 mg/kg/day by I.V. infusion in divided doses every 4 or 6 hours. Respiratory tract infections: (The usual dose is 3 grams given every 4 hours [18 grams/day] or 4 grams given every 6 hours [16 grams/day] depending on weight and the severity of the infection.) Urinary tract infections: Complicated: 150 to 200 mg/kg/day by I.V. infusion in divided doses every 4 or 6 hours. (Usual recommended dosage for average [70 kg] adults: 3 grams q.i.d.) Uncomplicated: 1 gram I.M. or direct I.V. every 6 hours.

Route of Administration: Other

In Vitro Use Guide

A total of 632 clinical bacterial isolates were tested for susceptibility to twofold dilutions of ticarcillin alone and in combination with 1, 2, and 4 micrograms of clavulanic acid (CA) (Timentin) per ml by a reference microdilution method. With the addition of CA, ticarcillin MICs were reduced eightfold or greater with 54 of 59 (92%) strains of the family Enterobacteriaceae with ticarcillin MICs of greater than or equal to 64 micrograms/ml. Ticarcillin MICs for beta-lactamase-producing Haemophilus influenzae, Neisseria gonorrhoeae, and most Staphylococcus aureus were reduced to less than or equal to 0.5 micrograms/ml when CA was added.

Name

Type

Language

TICARCILLIN

Official Name

English

ticarcillin [INN]

Common Name

English

Ticarcillin [WHO-DD]

Common Name

English

4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 6-(((2R)-2-CARBOXY-2-(3-THIENYL)ACETYL)AMINO)-3,3-DIMETHYL-7-OXO-, (2S,5R,6R)-

Common Name

English

TICARCILLIN [MI]

Common Name

English

TICARCILLIN [VANDF]

Common Name

English

(2S,5R,6R)-6-(((2R)-2-CARBOXY-2-(3-THIENYL)ACETYL)AMINO)-3,3-DIMETHYL-7-OXO-4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID

Systematic Name

English

Classification Tree Code System Code

NDF-RT

N0000011281